GILD - Gilead Sciences, Inc.
| Previous Close | 64.22 |
| Open | 64.07 |
| Bid | 63.72 x 1800 |
| Ask | 64.50 x 2200 |
| Day's Range | 63.87 - 64.22 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 157,182 |
| Avg. Volume | 6,153,473 |
| Market Cap | 81.104B |
| Beta (3Y Monthly) | 1.17 |
| PE Ratio (TTM) | 13.88 |
| EPS (TTM) | 4.61 |
| Earnings Date | Oct 23, 2019 - Oct 28, 2019 |
| Forward Dividend & Yield | 2.52 (3.93%) |
| Ex-Dividend Date | 2019-09-12 |
| 1y Target Est | 80.49 |
- Zacks
The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson
The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson
- Zacks
Novo Nordisk's Fiasp Gets EC Approval for Label Expansion
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
- Zacks
Top Research Reports for Union Pacific, Lowe's & Gilead
Top Research Reports for Union Pacific, Lowe's & Gilead
- Zacks
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
- Zacks
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
- Motley Fool
3 Dividend Stocks That Should Pay You the Rest of Your Life
Looking for payers you can count on? Then this trio should be right up your alley.
- Zacks
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
- Business Wire
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA.
CNW GroupQuébec Provides Access to Biktarvy® for the Treatment of HIV
Gilead Canada recognizes Québec's Ministry of Health for providing access to new HIV treatment, listed under the "Régie de l'assurance maladie du Québec" List of Medications According to the ...
- Zacks
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
- Zacks
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
- Zacks
Mergers & Acquisitions Take Center Stage in Biotech Industry
Mergers & Acquisitions Take Center Stage in Biotech Industry
- Zacks
Is Gilead Sciences (GILD) a Great Stock for Value Investors?
Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
- Simply Wall St.
What Kind Of Investor Owns Most Of Gilead Sciences, Inc. (NASDAQ:GILD)?
A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us which group is most powerful...
- Motley Fool
3 Embarrassingly Cheap Dividend Stocks
High yields. Low valuations. But with a couple of downsides to be aware of.
- Zacks
Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss
Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.
- Zacks
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.
- Zacks
Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.
- Business Wire
China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Gilead Sciences, Inc. (GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. In China, Biktarvy is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. “Biktarvy offers high rates of efficacy, high barriers to resistance and a demonstrated tolerability profile, underscoring its role as an important new treatment option for a broad range of patients in China,” said Professor Taisheng Li, Director of Infectious Disease Department, Peking Union Medical College Hospital.
- Zacks
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
- Business Wire
Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
F/TAF) for the proposed indication of pre-exposure prophylaxis (PrEP) in men and transgender women (TGW) who have sex with men by a vote of 16 to 2. “We appreciate the advisory committee’s thoughtful review and discussion of the data during today’s meeting and look forward to collaborating with FDA to make this potential new prevention option available to people at risk of HIV in the United States,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences.
- Reuters
Patient groups push back against Gilead's pricey HIV prevention treatment
Gilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates. Such groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. A generic version of the current prevention pill, Truvada, is due in the United States in September 2020, which should bring down costs and give many more people access to the therapy, they say.
- Zacks
Biotech ETFs in Focus on Impressive Q2 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
- Business Wire
Ontario Provides Access to Biktarvy® for the Treatment of HIV
MISSISSAUGA, Ontario-- -- Gilead Canada recognizes the Ontario Ministry of Health for providing access to new treatment for people living with HIV According to the most recent Public Health Agency of Canada data, Ontario accounts for the highest number and proportion of reported HIV cases 1 In clinical trials, BIKTARVY demonstrated high efficacy and a high barrier to resistance Gilead Sciences Canada, ...
